Blocking PRMT5 might force resistant brain-tumor cells into senescence, study suggests

(Ohio State University Wexner Medical Center) A new study by researchers at The Ohio State University Comprehensive Cancer Center -- James Cancer Hospital and Solove Research Institute suggests that blocking an enzyme called PRMT5 in tumor cells could be a promising new strategy for the treatment of glioblastoma, the most aggressive and lethal form of brain cancer.